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Abstract. A dual-functional device is fabricated to release progressively dopamine (DA) from 
a biohydrogel under real-time monitoring via electrochemical detection. For this purpose, a 
poly-γ-glutamic acid biohydrogel is assembled with a poly(3,4-ethylenedioxythiophene) 
(PEDOT) layer, previously deposited onto a screen printed electrode. The biohydrogel is 
formulated to achieve dimensional stability and maximum DA-loading capacity. Conditions 
for DA-loading are influenced by the oxidation of the neurotransmitter in acid environments 
and the poor resistance of PEDOT to the lyophilization. The performance of the device is 
proved in a medium with the physiological pH of blood and the cerebrospinal fluid. The 
progressive release of DA is successfully monitored by the device, the limit of detection and 
sensitivity of the integrated sensor being 450 nM and 8·10-5 mA/µM, respectively. The effect 
of electrochemical stimulation in the kinetics of the DA release is also investigated applying 
potential ramps in cyclic phase to alter the biohydrogel morphology.  
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1. Introduction  
Dopamine (DA) is a catecholamine that acts as a neurotransmitter, transmitting signals 
between the nerve cells of the brain and helping to regulate movement, emotional responses, 
pleasure, pain and motivation. The temporal fluctuation of DA concentration in the human 
brain has a critical effect on neurodegenerative disorders very relevant in current society, such 
as Parkinson's disease, Harrington's disease, bipolar disorder and attention deficit disorder.[1] 
This neurotransmitter is also associated with some psychological conditions, such as 
psychosis and schizophrenia.[2] 
Although DA can be monitored using a wide variety of techniques (e.g. spectroscopy and 
colorimetry),[3] the most straightforward technique for monitoring of inherently redox active 
DA are the electrochemical methods, which allow its discrimination from other structurally 
related neurotransmitters and from interferents (e.g. uric acid in the blood and ascorbic acid in 
the brain). Because of the central role of DA, thousands of papers have been published during 
the last decades on its electrochemical detection and sensing,[3] many of them covered in 
recent very good reviews.[4] On the other hand, the administration of DA can help to relieve 
the symptoms of some of the above mentioned disorders, as for example Parkinson's disease 
in which the progressive degeneration of the nigrostriatal dopaminergic system causes DA 
loss.[5] Currently, oral administration of DA precursor levodopa (L-DOPA) remains the gold 
standard for the treatment of these disorders, even though in many cases therapeutic effects 
decrease over the long-term (i.e. a gradual increment of the drug dose is required) and motor 
fluctuation may result as a side effect of the treatment. In order to relieve the undesirable 
effects of L-DOPA, in the last few years a few nanomaterials-based delivery systems have 
been developed for the targeted release of DA (e.g. nanoparticles,[6] carbon nanotubes,[7] 
carbon dots[8] and 3D hierarchical nanostructures[9]). In this work we propose an integrated 
bioplatform for the simultaneous detection and release of DA. From a fundamental 
perspective, this promising dual-functionalizing strategy offers a distinctive design principle 
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for real-time monitoring of progressively released neurotransmitters and opens a window for 
the development of devices for theranostic therapeutics for neurodegenerative diseases.  
 
2. Experimental section 
Materials and Methods are available in the Supporting Information. Details about the 
manufacture of the different components of the dual-functionalized device are provided in the 
Supporting Information. 
 
3. Results and Discussion 
The procedure used to fabricate the device for release and detection of DA, hereafter 
abbreviated RD-DA, is summarized in Figure 1. The RD-DA is based on a screen printed 
electrode (SPE in Figure 1A) that contains a carbon working electrode (WE), a platinum 
auxiliary electrode (AE) and a silver reference electrode (RE). Firstly, the carbon WE with 4 
mm in diameter is modified by poly(3,4-ethylenedioxythiophene) (PEDOT), which is 
obtained by anodic polymerization of 3,4-ethylenedioxythiophene (EDOT) monomers under a 
constant potential of 1.40 V (Figure 1B). The sheet-like compact structure of the bare carbon 
WE (Figure 2A) changes considerably after electrodeposition of the PEDOT layer. SEM 
micrographs of PEDOT-coated SPE show a sponge-like morphology with pores that facilitate 
the access and escape of electrolyte ions during electrochemical redox processes (Figures 2B-
C). After this, a thick (2 mm) Teflon® film with a hole of the same diameter as the WE is 
placed onto the modified SPE to protect both the AE and RE (Figure 1C), which are essential 
for the electrochemical detection process. Then, the PEDOT-modified WE is coated with a 
thin gelatin layer (1 µL of 10 w/v gelatin solution) to facilitate the adhesion between the 
PEDOT layer and the hydrogel used for DA loading and release (Figure 1D).  
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After this, a disulfide-cross-linked poly-γ-glutamic acid (γ-PGA) hydrogel matrix is 
synthesized in situ onto the gelatin layer. γ-PGA is a poly(γ-peptide) derived from glutamic 
acid (Glu), in which peptide bonds involve the γ-carboxyl group and α-amino groups (Figure 
1E). This compound, which is naturally synthetized as a slime layer by a variety of members 
of the genus Bacillus,[10] is commercially used in cosmetics, medicine, and industrial products 
(e.g. water absorption agents, moisturizing agents, thickening agents, absorption enhancers of 
minerals, sustained release drug delivery systems, and biodegradable agglomerated 
detergents).[11] In this work γ-PGA chains have been chemically cross-linked using a water 
soluble cystamine (WSC) as cross-linker agent, which regulates the characteristics of the 
resulting biohydrogel (i.e. cross-linking density, pore size, water absorption, and 
degradability),[12] and ethylcarbodiimide methiodide (EDC) as condensing agent (Figure 1E).  
SEM micrographs displaying the PEDOT/gelatin/γ-PGA interfaces are displayed in Figures 
2D-F. The boundaries of the PEDOT film and the gelatin layer are very well defined at the 
corresponding interface, whereas a biphasic interface in which the γ-PGA hydrogel penetrates 
into the gelatin separates such two materials. The formation of this biphasic region, which is 
of micrometric thickness, is consequence of the diffusion of the γ-PGA chains through the 
gelatin layer and their subsequent reticulation during the synthesis of the biohydrogel. 
Besides, comparison of the pores at both the biphasic region and the external sides of the 
hydrogel (Figures 2D-F) with those the internal region (Figure 2G) reflects important 
differences. Thus, pores are significantly larger in the former zones than in the internal region 
since the diffusion of WSC molecules inside the gelatin and towards the external sides is 
limited by the own gelation reaction. Consequently, the crosslinking degree is higher at the 
internal region, which affects the size of the pore.  
After removing the Teflon® film, the assembled device was washed with distilled water for 1 
h to eliminate the excess of EDC and achieve the maximum swelling (Figure 1F). The 
morphological characteristics of the hydrogel, which were defined during the synthetic 
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process through the γ-PGA:WSC:EDC ratio, and the choice of the swelling medium were 
critical to optimize the DA loading process in the assembled device, as is detailed below. 
Then, the DA was incorporated into the γ-PGA hydrogel through osmotic loading using a 
citric acid / sodium citrate buffer solution (pH 4.5) with 6 mg/mL DA as incubation medium 
(Figure 1G). This acid environment protected the DA molecule from oxidative degradation 
processes. Finally, the excess of DA adsorbed onto the surface of the γ-PGA hydrogel was 
eliminated by washing with phosphate buffered saline (PBS) solution at pH 7.2 (Figure 1H). 
After this, the integrated RD-DA was ready to be used as a dual-functional device capable of 
monitoring the release of DA in real-time (Figure 1I).  
Crucial points in this fabrication process were the selection of PEDOT as electrode material 
and properties of the γ-PGA matrix, especially the dimensional stability of the biohydrogel, 
which is related with its swelling capacity, and the DA-loading ability. The selection of 
PEDOT was motivated by the stability of this conducting polymer, which is significantly than 
that of other polyheterocycles as polypyrrole, and its ability for the selective determination of 
very low DA concentrations (i.e. from 60 to 500 nM depending on the presence or not of 
electrocatalysts).[13] It is worth noting that the electrochemical stability of the RD-DA device 
is defined by the performance of the PEDOT electrode. The stability of PEDOT for DA 
detection was examined by investigating the variation of the oxidation peak intensity against 
the number of consecutive oxidation-reduction cycles for 1 mM DA in 0.1 M PBS. After 25 
consecutive cycles, the reduction of the peak intensity was 8% only, demonstrating the good 
properties of the selected conducting polymer. 
On the other hand, the properties of the γ-PGA matrix strictly depend on the formulation of 
the prepared hydrogels. In this work seven different γ-PGA biohydrogels with different cross-
linking characteristics were prepared by combining the following parameters: (i) γ-PGA 
average molecular weight (Mw = 350,000 and 2,000,000); (ii) the γ-PGA : WSC ratio; and 
(iii) the EDC : γ-PGA ratio. The synthetic procedure, which was adapted from the one 
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described by Matsusaki et al.,[14] is described in the Supplementary Information. For brevity, 
the discussion of different observed behaviors is focused on the three hydrogels that provided 
better results (Table S1). These are LPGA-1 and LPGA-2, which were obtained using low 
molecular weight γ-PGA (Mw = 350,000) and a γ-PGA / EDC /WSC ratio of 5 / 5 / 1.5 and 5 
/ 5 / 2.5, respectively, and HPGA-1 that was derived from high molecular weight γ-PGA (Mw 
= 2,000,000) using a γ-PGA / EDC /WSC ratio of 5 / 5 / 2.5. 
The swelling ratio (SR) of the hydrogels depends on both their chemical formulation and the 
pH, as is described in the Supplementary Information. Considering that the pKa of non-
crosslinked carboxylate groups is ∼ 2.2, neutral solutions produced higher SRs than acid ones 
in all cases (Table S2), which could affect the dimensional stability of the RD-DA device (i.e. 
when swollen, the hydrogel could cover the area of the electrodes, AE and RE, and hinder the 
monitoring of released DA). However, this effect was smaller for the formulation of the 
LPGA-2 biohydrogel (SR= 517%±49% and 793%±15% after 48 h immersed in buffers with 
pH 4.5 and 7.3, respectively) than for LPGA-1 and HPGA-1. The response of the LPGA-2 
hydrogel after immersion in distillate water for 3 h is illustrated in Figure 3A. Moreover, 
analysis of the dynamic response of LPGA-2 against the change of pH (Figure 3B) reflected 
that the SR stabilizes much more quickly at pH 7.3 (∼1 h) than at pH 4.3 (∼24 h).  
Conditions for the DA-loading into the γ-PGA hydrogel were optimized considering the 
following variables: (i) the formulation of the hydrogel (i.e. three selected hydrogels, Table 
S1); (ii) the concentration of DA in the incubation solution (i.e. 3 and 6 mg/mL); and (iii) the 
pH of the incubation solution (i.e. pH 7.2, 4.5 and 2.2). Although DA was successfully loaded 
in all tested conditions, this neurotransmitter underwent a drastic oxidation when a 
hydrochloric acid / chloride buffer solution with pH 2.2 was used as loading medium (Figure 
S4). In spite of this, some hydrogel formulations showed an outstanding behavior, favoring a 
    
 - 8 - 
very rapid loading of DA and, subsequently, acting as protection element against oxidation 
processes (Figure 3C).  
Finally, the medium selected for DA loading was the citric acid / phosphate buffer (pH 4.5) 
with 6 mg/mL of neurotransmitter. Although immersion of lyophilized hydrogels into such 
medium ensured a very fast loading process, unfortunately, the PEDOT layer deposited on the 
SPE was not strong enough to withstand the lyophilization process without deterioration. 
Accordingly, the DA loading was carried out by osmosis, immersing the device without 
lyophilizing the γ-PGA hydrogel into the selected medium during 24 h. After this, the 
superficial DA was eliminated by washing the device with PBS (pH 7.2). It is worth noting 
that, in such conditions, UV-vis measurements showed that the concentration of DA in the 
residual loading medium was identical to the initial one (6 mg/mL), evidencing that this was 
also the amount of DA inside the hydrogel once the osmotic equilibrium was reached.  
Figure 4 proves the remarkable performance of the loaded RD-DA integrated device once it 
immersed into the release medium, which consisted in phosphate buffer solution at pH 7.3 
(physiological pH of blood and cerebrospinal fluid). Figure 4A compares the evolution of the 
DA concentration potentiodynamically detected by the RD-DA system with those determined 
using conventional spectroscopic and electrochemical measures, hereafter denoted controls 1 
and 2, respectively. As the concentration of DA in the medium increases with time, results 
from the controls demonstrate the release capacity of the RD-DA device. Results from control 
2, which is based on cyclic voltammetry (CV) measurements using independent SPE 
electrodes coated with PEDOT but without hydrogel, are influenced by the high affinity of 
DA towards PEDOT and, in general, towards conducting polymers.[13,15] Thus, control 2 
detects the local accumulation of DA onto the surface of the electrode, which is not 
considered by UV-vis spectroscopic measurements, explaining the quantitative differences 
between the two controls (Figure 4A). This feature is corroborated by the fact that, after 50 
min, such accumulation saturates and, therefore, the DA concentration detected by control 2 
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does not increase. In contrast to controls 1 and 2, the RD-DA device detects the DA 
remaining in the hydrogel, as is evidenced by negative slope of the detection profile, 
reflecting that the concentration of loaded DA decreases with time. Thus, in the recorded 
voltammograms the peak intensity of the DA oxidation with anodic peak potential at ∼0.3 V 
decreases when the immersion time of the RD-DA device into the release medium increases 
(Figures 4B-C).  
The limit of the detection (LOD) of the sensor integrated into the RD-DA device was derived 
from the variation of the anodic peak intensity (ip), as determined by cyclic voltammetry, 
against the DA concentration. The LOD expressed as 3.3·σ/S, where σ and S are the standard 
deviation of the response and the slope of the calibration plot for DA concentrations ranging 
from 3 to 600 µM is 450 nM. The sensitivity, which corresponds to the slope of calibration 
plot, is defined as the minimum DA concentration in the medium required to produce a 
certain current density in the output voltammogram. In the case of the RD-DA device the 
experimentally measured sensitivity is 8·10-5 mA/µM.  
The influence of electrochemical stimulation in the DA release was explored by applying 
several electrode potential ramps in cyclic phase that were additional to the one used for 
monitoring the neurotransmitter concentration. In practice, the electrochemically stimulated 
RD-DA device was submitted to three consecutive redox cycles each time that DA 
concentration was measured, while in absence of stimulation the only redox cycle applied was 
the one employed for monitoring. The shape of the profiles showing the DA remaining in RD-
DA devices when immersed in PBS at pH 7.3 was in general independent of the 
electrochemical stimulation (Figure 4D), even though the applied cyclic potential ramps 
clearly affected the kinetics of the release at the first ∼40 hours. Thus, the application of the 
potential caused a significant delay in the initial release of DA from the γ-PGA biohydrogel 
(e.g. 50% of DA was released after 3 and 10 h in absence and presence of electrochemical 
stimuli, respectively). However, the effect of such stimuli is null after 40 h, when around 85% 
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of DA has been released. This phenomenon has been attributed to the effect of the potential 
ramps on the porous morphology of the LPGA-2 hydrogel matrix, which transforms into a 
closed structure (Figure S5). The morphological alteration induced by electrochemical 
degradation is possible because of the flexibility of both the γ-PGA chains and the crosslinks. 
Thus, conformational movements of crosslinked polymer chains result in a reduction of the 
free volume (i.e. the hydrogel shrink), making difficult the diffusion of DA molecules towards 
the release medium. In spite of the success of electrochemically stimulated assays, future 
improvements in the design of the RD-DA device (e.g. replacing the gelatin layer used to 
assemble the electrode and the biohydrogel by a surface functionalization) could help regulate 
DA release more efficiently. Our future work will be oriented in this direction. 
 
4. Conclusions 
In summary, a DA release device able to monitor the delivered neurotransmitter has been 
developed by assembling a conducting polymer and a biohydrogel through a gelatin 
intermediate layer. The design and characteristics of the RD-DA device has been optimized to 
preserve the detection capacity of the SPE used as substrate and dimensional stability of the 
biohydrogel. Moreover, the DA-loading capability of the selected γ-PGA hydrogel is very 
high, making the RD-DA device a promising starting point for the development of theranostic 
therapeutic systems for neurodegenerative diseases. Besides, simple potential ramp assays 
have evidenced that the RD-DA device is electrochemically responsive. Although much work 
is still required to use this response as a tool to strictly control the DA release, this strategy 
may offer an excellent opportunity for the development of a second generation of RD-DA 
devices. Our future work is oriented towards the achievement of electro-responsive dual-
functionalization devices. 
 
Supporting Information 
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Figure 1. Schematic representation of the procedure for fabricating the integrated RD-DA 
(release and detection of DA) device: (A-B) Polymerization of PEDOT onto a SPE; (C-F) 
Assembly of the γ-PGA hydrogel matrix; (G-H) loading with DA; (I) Simultaneous release 
and detection of DA using the dual-functional RA-DA device. 
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Figure 2. SEM micrographs of: (A) the carbon WE in SPE; (B and C) PEDOT-coated SPE 
(low and high resolution, respectively); (D-F) PEDOT/gelatin/γ-PGA hydrogel interfaces (a 
representative cross section image is displayed in F); (G) interior region of the γ-PGA 
hydrogel; (H-I) top region of RD-DA device. In all cases the γ-PGA hydrogel corresponds to 
the LPGA-2 (Table S1). 
 
 
  
    
 - 16 - 
 
 
 
 
 
 
Figure 3. (a) Change of dimensions (base × height) in two representative samples of the 
LPGA-2 biohydrogel, adhered to the gelatin coating the PEDOT-modified WE, after 
immersion in distillate water during 3 h. (b) Swelling profile of LPGA-2, expressed as 
variation of the swelling ratio (SR) against time, with cyclical changes in the pH of the 
medium. Light blue regions indicate the periods of time in which the hydrogel is immersed in 
a phosphate buffer with pH 4.5, while light pink regions correspond to periods of time in the 
phosphate buffer saline solution with pH 7.3 (the change of pH is also described by red 
dashed line). (c) Representative experiments for DA-loading into LPGA-1 (pH 4.5) and 
LPGA-2 (pHs 4.5 and 2.2). Images display the aspect of the hydrogels after 4 h of incubation 
into a DA-containing (6 mg/mL) citric acid / phosphate (pH 4.5) and hydrochloric acid / 
chloride (pH 2.2) buffers.  
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Figure 4. (a) Temporal evolution of the concentration of DA when the loaded RD-DA device 
is immersed into the release medium. The profiles obtained using control 1 (UV-vis 
spectroscopy) and control 2 (CV using a SPE coated with PEDOT) corresponds to the DA 
released to the bulk and to the DA accumulated onto the electrode, respectively. The profile 
determined using the own RD-DA device displays the progression of the neurotransmitter 
loaded into the hydrogel. (b) Cyclic voltammograms (scan rate: 50 mV/s) obtained using the 
integrated RD-DA device after 30 min, 1 h and 2 h of immersion into the release medium. (c) 
Variation of the peak oxidation potential for DA at the electrode integrated into the RD-DA 
device against time when immersed into the release medium. (d) Effect of the electrochemical 
stimulation in the release profile of DA when the loaded RD-DA device is immersed in PBS 
at pH 7.3. Electrochemical stimulation consisted in the application of the three consecutive 
redox cycles (i.e. cyclic potential ramps changing 50 mV per second) each time that the DA 
remaining in the device is monitored. 
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A unique dopamine release device able to monitor continuously the delivered 
neurotransmitter is developed by assembling a conducting polymer and a biohydrogel. 
The limit of detection and sensitivity of the integrated sensor is 450 nM and 8·10-5 mA/µM, 
respectively. 
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